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Abstract
Background: High mobility group box 1 protein (HMGB1) is a major endogenous danger signal that triggers inflammation
and immunity during septic and aseptic stresses. HMGB1 recently emerged as a key soluble factor in the pathogenesis of
various infectious diseases, but nothing is known of its behaviour during herpesvirus infection. We therefore investigated
the dynamics and biological effects of HMGB1 during HSV-2 infection of epithelial HEC-1 cells.
Methodology/Principal Findings: Despite a transcriptional shutdown of HMGB1 gene expression during infection, the
intracellular pool of HMGB1 protein remained unaffected, indicating its remarkable stability. However, the dynamics of
HMGB1 was deeply modified in infected cells. Whereas viral multiplication was concomitant with apoptosis and HMGB1
retention on chromatin, a subsequent release of HMGB1 was observed in response to HSV-2 mediated necrosis. Importantly,
extracellular HMGB1 was biologically active. Indeed, HMGB1-containing supernatants from HSV-2 infected cells induced the
migration of fibroblasts from murine or human origin, and reactivated HIV-1 from latently infected T lymphocytes. These
effects were specifically linked to HMGB1 since they were blocked by glycyrrhizin or by a neutralizing anti-HMGB1 antibody,
and were mediated through TLR2 and the receptor for Advanced Glycation End-products (RAGE). Finally, we show that
genital HSV-2 active infections also promote HMGB1 release in vivo, strengthening the clinical relevance of our experimental
data.
Conclusions: These observations target HMGB1 as an important actor during HSV-2 genital infection, notably in the setting
of HSV-HIV co-infection.
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Introduction
High mobility group box 1 (HMGB1), an abundant nuclear
protein, is the main prototype of the ‘‘alarmins’’, a group of
molecules that contribute to establishing immunity in response to
cell damage. Extracellular HMGB1 derives either from active
secretion by immunocompetent cells or from release by necrotic
cells and by some apoptotic cells, a process that may be regulated
at least in part by autophagy [1,2]. Once outside the cell,
HMGB1 coordinates various cellular responses, linking septic or
aseptic stress signals to innate immunity and tissue repair.
Importantly, HMGB1 extracellular activity is modulated by post-
translational modifications. Notably oxidation of HMGB1 has
been regarded as an important mechanism to negatively or
positively regulates its extracellular activities [3,4,5]. The first
HMGB1 receptor to be identified was RAGE [6], but HMGB1
also contributes to the activation of several immune receptors,
including TLR-2 and -4 [7]. Extracellular HMGB1 can act by
itself and/or in association with molecules such as CpG DNA,
LPS and IL-1b [8].
Whereas the role of HMGB1 during bacterial infections has
been extensively investigated, notably during severe sepsis [9], its
dynamics and potential impact during viral infections remain
largely unknown. In particular, the possible contribution of
HMGB1 to the signalling or modulation of HSV-2 infection has
not yet been addressed.
The prevalence of HSV-2 infection, the main cause of genital
herpes, is growing. It reaches 30% among pregnant women in
western countries and is even higher in selected populations and
developing countries. Importantly, between 60% and 95% of
HIV-infected individuals are also infected by HSV-2 [10].
Observational and experimental studies have shown a deleterious
effect of HSV-2 on both HIV-1 transmission and disease
progression [11]. Recent proof-of-concept trials have examined
the impact of anti-herpetic therapy on HIV-1 viral load in plasma
and/or genital secretions [12] [13] [14].
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significant role during HSV-2 infection. First, both epithelial cell
damage and immune activation are observed during HSV-2
infection, and these two events may promote local HMGB1
release. Furthermore, soluble factors present in the genital tract,
including CXC- and CC-type chemokines and interferon-b are
crucial for an efficient immune response to HSV-2 [15]. The
release of these molecules is triggered at least in part by interaction
of cellular and/or viral components with several TLRs, particu-
larly TLR-9 and TLR-2 [16]. TLR-2 is a known receptor for
HMGB1, and HMGB1 has been shown to stimulate TLR-9
activation by DNA species in a RAGE-dependent manner [17].
Finally, some forms of HMGB1 act as chemoattractants or pro-
inflammatory cytokines, and may modulate HIV-1 expression.
These activities could be critical during HSV-2 infection,
especially in a context of HIV-1 co-infection.
However HMGB1 dynamics and biological activities during
active herpes simplex infection are especially difficult to predict.
First, some HSV-2 gene products, such as ICP-10, can either be
pro- or anti-apoptotic according to the cell type [18]. In the
context of infection, the process of HSV-induced cell death, results
from an even more complex balance between pro- and anti-
apoptotic signals, which is also influenced by both the cell type and
the origin of the viral strain [19,20]. In addition, since numerous
biologically active factors are released during HSV-2 infection, the
precise contribution of HMGB1 needs to be determined.
This study was designed to examine three important issues. We
first analyzed the modulation of HMGB1 transcription and
dynamics during HSV-2 infection of epithelial cells from endome-
trial origin, with respect to virus multiplication and virus-induced
cell damage. We then examined whether HMGB1 released during
HSV-2 infection is biologically active. Finally, we studied HMGB1
accumulation in vivo in the genital tract of HSV-2-infected women.
Results
HSV-2 infection inhibits HMGB1 transcription in HEC-1
cells
HEC-1 cells, derived from a human endometrial cancer, were
used as a model of epithelial cells. As HSV infection can repress
the expression of cellular proteins through transcriptional and
post-transcriptional mechanisms [21,22], we examined whether
HSV-2 infection down-regulates HMGB1 expression as well.
A marked decrease in HMGB1 transcription was observed as
early as 3 h post-infection (pi) and reached 98% after 48 h
(Figure 1A). Surprisingly, the HMGB1 protein level was barely
affected (Figure 1B). This remarkable stability of HMGB1 was not
directly due to HSV-2 infection, as it was also observed in
uninfected cells treated with actinomycin D (Figure 1C).
HSV-2 replicates and induces both apoptosis and
necrosis in HEC-1 cells
Virus-associated cell damages were analyzed in relation with
virus multiplication. A strong cytopathic effect was observed in
most of the cells infected at 1 pfu/cell at day 1 pi (not shown).
Virus production reached a plateau at day 2 pi for the two MOIs
used (Figure 2A). Cell proliferation was inhibited on day 1, and cell
viability was reduced on days 2 and 3 (Figure 2B). Virus-associated
apoptosis, assessed by measuring PARP cleavage products and
pro-caspase 3 expression, started at 24h and peaked at 48 h pi
(Figure 2C), when viral production already reached a plateau
(Figure 2A). Marked chromatin condensation was also observed
microscopically in about 20% of cells on day 2 pi (not shown).
Necrosis occurred later, as shown by LDH release, which was
apparent on day 2 pi and increased over time in a dose-dependent
manner (Figure 2D). Importantly, necrosis required viral replica-
tion, as it was prevented by aciclovir.
Figure 1. HMGB1 transcription and expression during HSV-2 infection. HEC-1 cells were infected at 0.1 or 1.0 pfu/cell. A time-course
analysis of HMGB1 mRNA (A) and protein (B) was performed by quantitative RT-PCR and western blot, respectively, with 18S rRNA and GAPDH protein
as controls. RNA quantification was performed according to the 2
- DDCT method [50]. (C) HMGB1 was detected more than 4 days in HEC-1 cells
treated with actinomycin D. GADPH and P53 were used as controls. M = mock-infected cells. Results are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0016145.g001
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intended to evaluate the respective contribution of primary and
post-apoptotic necrosis. Inhibition of virus-mediated apoptosis by
the peptide Z-VAD did not decrease the necrotic process,
suggesting that necrosis did not occur as a consequence of
apoptosis. Rather treatment with Z-VAD increased necrosis at day
2 (Figure 2E), showing that virus-induced apoptosis prevent
necrosis in a significant number of HSV-2-infected cells.
HMGB1 mobility during HEC-1 cell infection by HSV-2
HMGB1 binds tightly to chromatin during some forms of
apoptosis [1] [23], but this phenomenon has never been
documented during viral infection. In a preliminary experiment,
we first verified that apoptosis induced by cycloheximide and
TNF-a was associated with HMGB1 retention on chromatin in
HEC-1 cells (Figure 3A).
In uninfected cells, HMGB1 was equally distributed between
the nucleus and the cytoplasm (Figure 3B), in keeping with its
constant shuttling between these compartments [24]. In the
presence of HSV-2, HMGB1 gradually moved from the cytosol
and transiently concentrated in the nucleus, suggesting that it was
retained on chromatin early after infection (Figure 3B). To test this
assumption, mobile and chromatin-bound HMGB1 fractions were
separated after cell permeabilization with NP40 as described in
[1]. As shown in Figure 3C, chromatin bound (CB) HMGB1
increased until day 2 pi, then fell slightly, concomitantly with
HMGB1 extracellular release (Figure 3D). HMGB1 release was
time- and dose-dependent, peaked on day 5 pi, and ran parallel to
HSV-2-induced necrosis (Figure 2D). For the highest MOI, the
leakage of HMGB1 out of the cells starts between day 2 and day 3
pi, which explains why HMGB1 concentration decreases in both
nuclear and cytosolic fractions at these time points (Figure 3B).
Contrary to previous observations made in post-apoptotic cells
[25], extracellular HMGB1 was not nucleosome-associated, as it
never copurified with histone in the culture medium (data not
shown).
Figure 2. HEC-1 cell death during HSV-2 infection. HEC-1 cells, infected at 0.1 or 1.0 pfu/cell, were analyzed at various times post-infection for
(A) HSV-2 productive infection, assessed by plaque assay, (B) cell viability, assessed by trypan blue exclusion, (C) apoptosis, assessed by western blot
against PARP and pro-caspase 3, and (D) necrosis, assessed by extracellular LDH release over total LDH. (E) Necrosis was measured in mock and HSV-
2-infected cells in the presence and absence of Z-VAD, an inhibitor of apoptosis. Results are either representative of at least 3 independent
experiments (A, B, C) or are means and SD from 3 independent experiments (D, E).
doi:10.1371/journal.pone.0016145.g002
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with apoptosis and HMGB1 retention on chromatin, followed by
necrosis and extracellular HMGB1 release.
HMGB1 released during HSV-2 infection induces cell
migration and reactivates latent HIV-1
HMGB1 released by HSV-2 infected cells might contribute to
signaling of the infection and modify the environment of infected
cells in vivo. However, HMGB1 extracellular activities can be
modulated positively or negatively, by oxidation in necrotic and
apoptotic cells [3] [5] [4] and/or by interactions with a large set of
molecules of cellular or viral origin [8].
We first examined the chemotactic activity of culture superna-
tants by using human MRC5 fibroblasts. Preliminary experiments
indicated that recombinant human HMGB1 stimulated MRC5
fibroblast migration (Figure 4A) through RAGE and TLR-2. A
slight HMGB1-independent increase in cell migration was
observed with supernatants from mock-infected cells (Figure 4B),
while supernatants of HSV-2-infected cells exhibited strong
chemoattractant activity (Figure 4B). This activity was largely
mediated by HMGB1 through TLR-2, as it was abrogated by
glycyrrhizin, an HMGB1 inhibitor [26], and also by neutralizing
anti-HMGB1 and anti-TLR2 antibodies, but not by antibodies
blocking RAGE or TLR-4. Similar results were obtained with 3T3
murine fibroblasts (not shown).
We have previously shown that cellular and recombinant forms
of human HMGB1 purified from Escherichia coli reactivate HIV-1
from post-integration latency in a RAGE-dependent manner,
notably in ACH-2 lymphocytes [27] (Figure 4C). As HIV-1 and
HSV-2 may functionally interact in the genital mucosa [28],we
wondered whether HMGB1 released by HSV2-infected cells
might modulate HIV-1 reactivation as well. Thus, ACH-2 cells
were exposed to supernatants collected from mock- and HSV-2-
infected cells. A 12-fold increase in p24 antigen expression was
observed in ACH-2 cells treated with crude supernatants from
HSV-2-infected cells relative to the control (Figure 4D). As HSV-2
itself can reactivate latent HIV-1 [29], infectious particles were
removed from the supernatants by ultracentrifugation. As
expected, HIV reactivation was lowered in the presence of
virion-free supernatants but remained still significant compared to
the control (Figure 4D). The addition of glycyrrhizin or blocking
anti-RAGE antibody totally abrogated HIV-1 reactivation,
Figure 3. HMGB1 mobility is altered by HSV-2 infection. HEC-1 cells were treated with TNF-a (2 ng/ml) and CHX (10 mg/ml). At various times
post-induction, western blot was performed on whole cell extracts to detect PARP and pro-caspase 3. A nuclear fraction obtained after NP-40-
induced membrane permeabilization was also subjected to western blot to detect chromatin-bound HMGB1 (bottom). (A) Time-course analysis of
HMGB1 in the cytoplasm and nucleus after HSV-2 infection of HEC-1 cells at 0.1 and 1.0 pfu/cell. M = mock-infected cells. (B) Time-course analysis of
mobile (M) and chromatin-bound (CB) HMGB1 during HSV-2 infection, following membrane permeabilization by NP40. (C) Measurement of
extracellular HMGB1 by ELISA after infection of HEC-1 cells by HSV-2. Results are representative of 3 independent experiments.
doi:10.1371/journal.pone.0016145.g003
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may still play a role in HIV-1 induction in the context of crude cell
extracts. Altogether, these results confirm that HSV-2 infection
promotes the release of HMGB1 in a biologically active form.
Detection of HMGB1 in cervico-vaginal secretions from
HSV-2-infected women
As HSV-2 infection induced the release of biologically active
HMGB1 in vitro, we examined whether active genital HSV-2
infection was associated with HMGB1 release in vivo, by
quantifying HMGB1 in cervico-vaginal samples collected from
18 HSV-2-infected women, during HSV-2 recurrence or not. Two
techniques were used i.e. a commercial ELISA and an original gel-
shift assay that was developed in our laboratory [30]. This assay
relies on the ability of HMGB1 to form highly specific and stable
complexes with hemicatenated DNA [31]. The correlation
between the two methods was excellent (p=0.0007, Spearman’s
Rank test), even if some discrepancies were sometimes observed,
especially for the highest concentrations of HMGB1 (Table 1).
Eight out of 18 samples exhibited HMGB1 concentration above
10 ng/ml and two of them contained a very high concentration of
HMGB1, above 500 ng/ml HMGB1 as estimated by gel shift
assay and above 100 ng/ml by ELISA (Figure 5, Table 1).
Importantly, a significant positive correlation was observed
between the amount of viral DNA, which reflects viral replication,
and HMGB1 concentrations, quantified either by gel shift
(p=0.05, rho value =0.46, Spearman’s rank test) or by ELISA
(p=0.02, rho value =0.56, Spearman’s rank test). This result
Figure 4. HMGB1 released by HSV-2-infected cells activates fibroblast migration and stimulates HIV-1 expression. MRC5 fibroblasts
were subjected to migration assays in the presence of (A) human recombinant HMGB1 or (B) supernatants from mock (M) or HSV-2-infected HEC-1
cells. HMGB1 concentrations reached 270 ng/ml in the supernatants collected from infected cells, versus 50 ng/ml in mock-infected cell media.
Control experiments used glycyrrhizin or neutralizing antibodies against HMGB1 or its receptors RAGE, TLR-4 and TLR-2. Data are expressed as -fold
increases in cell migration compared to non treated control cells. ACH-2 cells, that contain a latent HIV-1 provirus, were grown in the presence of (C)
human recombinant HMGB1 or (D) supernatants from mock (M) or HSV-2-infected HEC-1 cells. P24 antigen was measured by ELISA after 36 h. Data
are expressed as the -fold increase in p24 antigen compared with non treated control cells. Virion-free supernatants were obtained by
ultracentrifugation. Results are either representative of several experiments (A, C, D) or expressed as the mean and SD of 3 independent experiments
(B).
doi:10.1371/journal.pone.0016145.g004
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infected women.
patient viral culture HSV-2 DNA (copies/ml) HMGB1 (gel shift, ng/ml) HMGB1 (ELISA, ng/ml)
1 neg 0 0 4.5
2 HSV2 465.5 0 2.8
3 neg 0 3 2.7
4 CMV 0 2 12.1
5 neg 0 10 10.7
6 neg 0 0 5.4
7 HSV2 99500 540 129.3
8 neg 0 5 1.5
9 HSV2 3520 15 21.6
10 neg 0 10 2.6
11 neg 0 0 2.3
12 neg 0 0 2.3
13 neg 0 0 4.8
14 neg 0 23 19.4
15 HSV2 1355000 22 40.4
16 neg 0 550 113.1
17 neg 0 0 2.5
18 HSV2 5250 32 12.5
Eighteen genital samples were collected from women seropositive for HSV-2. Viral culture was performed on Vero cells, and HSV-2 DNA was quantified with real-time
PCR. HMGB1 was quantified with a commercial ELISA and a band-shift assay, as described in [32].
doi:10.1371/journal.pone.0016145.t001
Figure 5. Band-shift assay for HMGB1 detection in cervicovaginal secretions from HSV-2-infected women. Ten microliters of
cervicovaginal specimens (#1–18) collected from 18 women seropositive for HSV-2 were mixed with radiolabeled hemicatenated DNA (hcDNA).
HMGB1-hcDNA shifted complexes were analyzed by electrophoresis on nondenaturing polyacrylamide gel, using a band-shift assay, as described in
(30). The amount of HMGB1 was calculated from the percentage of shifted hcDNA, quantified with ImageJ software (table 1).
doi:10.1371/journal.pone.0016145.g005
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release of soluble HMGB1 in vivo as well, at least in the context of
genital infections.
Discussion
We show that HMGB1 expression and dynamics are profound-
ly altered during HSV-2 infection. Whereas HMGB1 constantly
shuttles between the nucleus and cytoplasm of HSV-2-uninfected
cells, it gradually concentrated in the nucleus and co-purified with
chromatin during the pro-apoptotic phase of the infection that
occurred from 24 to 48 hours post-infection in HEC-1 cells. This is
reminiscent of the HMGB1 retention observed in some models of
chemically induced apoptosis [1], even though this observation has
been challenged [23] [17] [3] and may depend either on the
nature of the apoptotic signal or on the cell type. Our data provide
the first evidence that virus-induced apoptosis can also stimulate
HMGB1 association with chromatin, a phenomenon that peaked
when virus production was already at a plateau. Nevertheless,
virus-induced necrosis still occurred later during the infection,
promoting massive release of HMGB1. HMGB1 release has
previously been reported during in vitro infection with RNA viruses
such as Dengue virus [32] [33] or HIV-1[34]. However, our study
is the first detailed investigation of HMGB1 release and activity in
a model of lytic DNA virus, where a balance between pro- and
anti-apoptotic signals has been shown to modulate the cell death
process and, as a possible consequence, the severity of the disease
[20]. Our results are notably different from those obtained with
HIV-1-infected lymphocytes, where HMGB1 release has been
linked to both apoptosis and necrosis, being inhibited in the
presence of apoptosis inhibitors [34]. The process is different
during HSV-2 infection, as inhibition of apoptosis by Z-VAD led
to increased necrosis, indicating that HSV-2-induced apoptosis
delays cell necrosis and subsequent HMGB1 release. This
phenomenon would be highly beneficial to the virus, as it could
allow the viral cycle to be completed without interference from
HMGB1-dependent immune responses. Contrary to the widely
accepted notion that apoptosis is a first line of defence against viral
infection; virus-induced apoptosis might rather favour virus
multiplication in vivo by limiting necrosis, a process that leads to
inflammation and activation of innate immune responses.
It has been reported that HMGB1 released during apoptosis or
necrosis is largely oxidized [35], which may affect its stimulatory
activity [3][5]. However, we show here that late release of
HMGB1 by infected epithelial cells displays at least two biological
activities that are highly relevant to herpetic infection. First,
culture medium from HSV-2-infected cells exhibited strong
chemoattractant activity for fibroblasts, mostly owing to the
presence of HMGB1. This finding is important, given the well-
known role of fibroblasts in herpetic lesions [36] and wound
healing [37], and suggests that HMGB1 may contribute to the
healing of herpetic genital lesions. In our model, fibroblast
migration was dependent on HMGB1-TLR2 interaction but did
not require RAGE, as previously observed in other cell models
[38].
Reversely, the alarmin activity of HMGB1 may be detrimental,
notably in HSV-2/HIV co-infection. The known deleterious
impact of HSV2 infection on HIV disease progression has been at
least in part linked to direct interplay between the two viruses [10].
The strong increase in HIV-1 expression in chronically infected T
cells exposed to HSV-2-infected HEC-1 cell supernatants, and its
partial reversal in the absence of viral particles, confirms the major
impact of HSV-2 particles on retrovirus expression [29]. However,
we also found that HMGB1 is the major soluble factor released by
HSV-2 infected cells that contributes to HIV-1 activation, since its
neutralization by glycyrrhizin totally abrogated HIV-1 reactiva-
tion by infectious virus-free supernatants. We and others have
previously shown that HMGB1 can reactivate HIV-1 both in vitro
and ex vivo [27,39]. This is therefore confirmed here, as HMGB1
released in response to HSV-2 infection specifically activated -
though moderately- HIV-1 in latently infected cells, in a RAGE-
dependent manner.
The endometrial epithelial cells used in our experiments may
not be fully representative of lower genital epithelia. However, the
relevance of our experimental data is strengthened by the
detection of biologically relevant concentrations of HMGB1 in
cervico-vaginal secretions from some HSV-2-infected women.
HMGB1 has been detected in the blood of patients with various
conditions, but few data are available on specimen collected from
sites of local inflammation or cell damage. Our study is the first to
show the presence of significant amounts of HMGB1 in the female
genital tract. Since cervico-vaginal washing fluids are rather
complex media, we quantified HMGB1 by two different methods,
a commercial ELISA and a band shift assay that is less prone to
interfering with masking proteins that might associate with
HMGB1 in vivo [30]. Importantly and whatever the method
used to quantify HMGB1, a positive correlation was observed
between HSV2 replication and HMGB1 concentrations in these
samples, which supports the involvement of HSV-2 in HMGB1
release through virus-mediated cell necrosis.
Besides being the first target of sexually transmitted HSV-2,
the genital epithelium plays a key role in triggering innate
immunity to microbial pathogens [40]. Among other pattern
recognition receptors, TLR-2 and TLR-9 have been implicated
in anti-HSV-2 immune responses through the recognition of still
unknown viral components [41] [40] [42] [16]. The key role of
TLR-2 during HSV-2 genital infection has been notably
highlighted by a decrease in HSV-2-specific responses observed
in TLR2 knock-down mice, intra-vaginally challenged with a
viral peptide epitope extended by a TLR-2 agonist [43].
HMGB1 likely contributes to this process by interacting with
TLRs, alone or together with nucleosomes [25]. Importantly, we
detected no free or HMGB1-associated histones in the
supernatants of HSV-2-infected HEC-1 cells, suggesting that
HMGB1 was not bound to post-apoptotic nucleosomes (not
shown). Alternatively, HMGB1 can form active complexes with
CpG DNA, which may enhance [17,44,45] or diminish [46]
TLR 9-dependent responses. As CpG motifs are abundant in the
HSV-2 genome [47], HMGB1 accumulation at the site of HSV-
2 infection could contribute to modulating an appropriate innate
response, notably through dendritic cell activation, and to
coordinating tissue repair in a mutually non exclusive manner.
These important issues are currently under investigation in our
laboratory.
Materials and Methods
Cell lines and virus
HEC-1 cells were from INSERM U743 (Paris, France). ACH2
cells, a subclone of HIV-1-infected human T cells, were from the
AIDS Research and Reference Reagent Program (Bethesda,
USA). Mouse 3T3 fibroblasts were kindly provided from Institut
de Ge ´ne ´tique et Microbiologie (Orsay, France) and human MRC5
fibroblasts from R/D Biotech (Besanc ¸on, France). Cells were
cultured at 37uC with 5% CO2 in RPMI medium (ACH-2 and
HEC-1 cells) or DMEM (MRC5 and 3T3 cells), supplemented
with 10% foetal bovine serum and 1% penicillin/streptomycin
(Invitrogen, Cergy-Pontoise, France).
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were inoculated with a clinical HSV-2 isolate of genital origin, at a
multiplicity of infection (MOI) of 0.001 per cell. On day 5 post-
infection, the cell supernatant was collected and clarified by
centrifugation. The virus stock was subsequently concentrated and
purified by ultracentrifugation (228 000 g, 2 h, 4uC). The resulting
virus pellet was resuspended in RPMI medium. The virus titer was
determined as described elsewhere [48]. A single stock
(4.2610
7 pfu/ml) was stored at 280uC and used for all
experiments.
HMGB1 transcription during HSV-2 infection
HMGB1 mRNAs were quantified in HEC-1 cells with a real-
time RT-PCR method, at various times post-infection. Total RNA
was extracted using the Trizol method (Invitrogen, Cergy-
Pontoise, France). One microgram of RNA was reverse tran-
scribed using 200 U of Moloney murine leukemia virus reverse
transcriptase (Invitrogen, Cergy-Pontoise, France).
PCR reactions were performed in a final volume of 20 ml,
containing master SYBRGreen (Roche Diagnostics, Meylan,
France) and 300 nM each HMGB1 primer, as previously
described [49].
Delta CT values were defined as the absolute difference
between the cycle threshold (CT) of HMGB1 RNA and the
house-keeping gene encoding 18S rRNA. Gene expression data
were analyzed with the 2
- DDCT method [50].
Cell viability analysis
Cell viability was assessed with the trypan blue exclusion
method. The role of apoptosis and necrosis in cell death was
examined with specific methods, as follows.
Lactate dehydrogenase (LDH) assay
Cell necrosis was evaluated by quantifying the release of the
stable cytosolic enzyme lactic dehydrogenase (LDH), using the
Cytotoxicity Detection kit from Roche Diagnostics (Meylan,
France) as recommended by the manufacturer. In one control
well, NP40 was used at a final concentration of 0.1% to determine
maximal LDH release.
The percentage of necrosis, evaluated by the ratio between the
amount of released LDH in the medium over the maximal LDH
release, was defined as OD experimental value /OD control *100.
Caspase 3 and PARP cleavage analysis. At appropriate
times post-infection, mock and HSV-2-infected cells were lysed in
RIPA buffer (0.25% sodium deoxycholate, 0.1% SDS, 1% NP-40
in PBS) containing protease inhibitors. Total protein (5 and 30 mg)
was separated by SDS-PAGE and submitted to western blotting
against pro-caspase 3 and PARP proteins, respectively. In some
experiments, cells were treated with the caspase inhibitor Z-VAD-
FMK (Promega, Yerres, France), at a concentration of 40 mM.
Intracellular HMGB1 dynamics
Subcellular distribution of HMGB1. The Subcellular
Proteome Extraction kit (Calbiochem) was used to separate
cytosolic, membrane, nuclear and cytoskeleton fractions.
HMGB1 was detected in each fraction by western blotting.
Cell permeabilisation assay. Chromatin-bound HMGB1
was collected from mock and HSV-2-infected cells after NP-40-
induced membrane permeabilization [1] and analyzed by western
blotting.
HMGB1 release. HMGB-1 released from mock and HSV-2-
infected cells was quantified with a commercial ELISA method
(Shino test, Kanagawa, Japan).
Western blotting
Proteins were separated by SDS-PAGE and transferred to
nitrocellulose membranes (Hybond, Amersham, Saclay, France).
The membranes were blocked for 1 h, then washed and incubated
with the following primary antibodies: anti-HMGB1 (clone 4C9),
anti-PARP (clone H-250), anti-histone H1 (clone AE-4), anti-pro-
caspase3 (clone E-8) and anti-GAPDH (clone 10B8) (Santa Cruz
Biotechnology, CA, USA) at 1:2000 dilution; and anti-LDH (clone
EP1566Y) (Abcam Cambridge, UK) at 1:20 000 dilution.
The secondary antibodies were a 1:5000 dilution of anti-rabbit
immunoglobulin-horseradish peroxidase or anti-mouse immuno-
globulin-horseradish peroxidase conjugates (Amersham, Saclay,
France). Immune complexes were detected with ECL detection
reagents (Amersham, Saclay, France).
Biological activities of HMGB1-containing supernatants
Supernatants collected on day 5 from mock and infected HEC-
1 cell cultures, were either used crude or after removal of infectious
particles by ultracentrifugation. The efficiency of this procedure
was checked by plaque assay as described [48]. When indicated,
the supernatants were treated with the HMGB1 inhibitor
glycyrrhizin (250 mM) or 10 mg/ml neutralizing antibodies against
RAGE (clone 176902, R&D systems, France), TLR-2 (clone TL2-
1, eBioscience) or TLR-4 (clone HTA 125, eBioscience). Protein
A-purified neutralizing rabbit anti-HMGB1 IgG (50 mg/ml) was
produced and also used for neutralization assays.
Chemotaxis assay
Chemotaxis assays were performed as previously described [51],
with the following minor modifications: mouse 3T3 and human
MRC5 fibroblasts and uncoated PVP free-polycarbonate filters
(Corning) were used, and cell migration lasted 4 h. Cells remaining
on the upper surface of the filters were mechanically removed, and
migrating cells were quantified after crystal violet coloration, as
described elsewhere [52].
HIV-1 p24 antigen production by chronically infected
lymphocytes
ACH-2 cells were grown in the presence of mock or HSV-2-
infected HEC-1 culture supernatants. HIV production was
evaluated by measuring p24 antigen with an ELISA method
(Innogenetics, Les Ulis, France).
Detection of HMGB1 in cervicovaginal secretions from
HSV-2-infected women
We used a collection of cervicovaginal secretions collected
during a randomized study of the impact of anti-herpetic therapy
on genital shedding of HIV-1 (ANRS 1212). This study was
approved by the research ethics committees of the Ministries of
Health of Ghana and the Central African Republic and the
London School of Hygiene & Tropical Medicine, and written
informed consent was obtained from all the participants. After
approval from the scientific committee of this ANRS study,
eighteen specimens collected from a group of women, infected by
HSV-2 but sero-negative for HIV-1, were analyzed. Cervicovag-
inal secretions were collected as described elsewhere [13,53] After
a centrifugation step to remove genital cells, supernatants were
stored at 220uC until use. Vero cells were used for viral culture,
and HSV-2 DNA was quantified by real time PCR, as described
[54].
HMGB1 was quantified in the same samples by using two
methods: a commercial ELISA test (Shino test, Kanagawa, Japan)
and a sensitive in-house gel shift assay, that was performed as
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specimens were mixed with radiolabeled hemicatenated DNA
(hcDNA) and HMGB1-hcDNA shifted complexes were analyzed
by electrophoresis on nondenaturing polyacrylamide gel. The
amount of HMGB1 was calculated from the percentage of shifted
hcDNA, quantified with ImageJ software.
Correlations between the two methods used to quantify
HMGB1, and between HMGB1 and HSV-2 DNA concentra-
tions, were identified with the Spearman’s rank correlation test
(software Stata, version, 10.0).
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